![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-Term Efficacy and Safety of E/C/F/TDF vs. EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected Treatment Naïve Subjects Age ≥ 50 Years
|
|
|
Reported by Jules Levin
HIV Drug Therapy Glasgow
Glasgow, UK
November 2-6, 2014
B Gazzard1, PM Girard2, G Di Perri3, J Gallant4, W Towner5, F Rogatto6,
J DeMorin7, D McColl7, HC Liu7, K White7, M Rhee7, J. Szwarcberg7, and D Piontkowsky7
1Chelsea and Westminster Hospital, London, UK; 2Center Hospital at University St Antoine, Paris, France;
3University of Turin School of Medicine, Torino, Italy; 4Southwest CARE Center, Santa Fe, NM; 5Kaiser Permanente, Los Angeles, CA;
6Gilead Sciences Europe Ltd., Stockley Park, UK; 7Gilead Sciences Inc., Foster City, CA
![Glascow1.gif](../images/110714/110714-1/Glascow1.gif)
![Glascow2.gif](../images/110714/110714-1/Glascow2.gif)
![Glascow3.gif](../images/110714/110714-1/Glascow3.gif)
![Glascow4.gif](../images/110714/110714-1/Glascow4.gif)
![Glascow5.gif](../images/110714/110714-1/Glascow5.gif)
![Glascow6.gif](../images/110714/110714-1/Glascow6.gif)
![Glascow7.gif](../images/110714/110714-1/Glascow7.gif)
![Glascow8.gif](../images/110714/110714-1/Glascow8.gif)
![Glascow9.gif](../images/110714/110714-1/Glascow9.gif)
![Glascow10.gif](../images/110714/110714-1/Glascow10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|